CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Berlin, Germany and 66 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Berlin, Germany and 73 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Berlin, Germany and 188 other locations
Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...
Phase 3
Berlin, Germany and 126 other locations
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...
Phase 2, Phase 3
Berlin, Germany and 76 other locations
cancer treatment and have also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it is...
Berlin, Germany and 13 other locations
in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...
Phase 2
Berlin, Germany and 53 other locations
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...
Phase 3
Berlin, Germany and 260 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Berlin, Germany and 216 other locations
doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal....
Phase 3
Berlin, Germany and 254 other locations
Clinical trials
Research sites
Resources
Legal